UBS Upgrades Immunovant to Buy, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Colin Bristow has upgraded Immunovant (NASDAQ:IMVT) from Neutral to Buy and raised the price target from $18 to $55.
October 13, 2023 | 9:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunovant's stock has been upgraded to Buy from Neutral by UBS, with a significant increase in the price target from $18 to $55.
The upgrade from Neutral to Buy indicates a positive outlook for Immunovant's stock. The significant increase in the price target from $18 to $55 suggests that UBS sees substantial upside potential for the stock. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100